Key result
Pre-admission DOACs or therapeutic VKAs reduce admission stroke severity in AF-AIS compared to no anticoagulation.
Why the study?
It is unknown whether different pre-admission anticoagulants impact the prognosis and admission severity of atrial fibrillation-related acute ischemic stroke.
Does pre-admission anticoagulation with DOAC or VKA reduce admission severity of acute ischemic stroke in patients with atrial fibrillation?
Meta-Analysis (n=9,493)
Does pre-admission anticoagulation with DOAC or VKA reduce admission severity of acute ischemic stroke in patients with atrial fibrillation?
Effect estimate: MD -2.96 (95% CI -3.75, -2.18)
p-value: p=< 0.00001
Pre-admission use of DOACs or therapeutic VKAs in patients with atrial fibrillation is associated with significantly reduced stroke severity on admission compared to no anticoagulation.
Authors
No takes yet. Share an insight, caveat, or question.
May support anticoagulation in AF to lessen stroke severity; confirms observational associations but remains hypothesis-generating.
García et al. (2022) conducted a meta-analysis in Atrial-Fibrillation-Related Acute Ischemic Stroke (n=9,493). Direct oral anticoagulants (DOAC) or therapeutical vitamin K antagonists (VKA) vs. No anticoagulation was evaluated on Admission severity of AF-AIS (MD -2.96, 95% CI -3.75, -2.18, p=< 0.00001). Pre-admission treatment with DOACs (MD -2.96; 95% CI -3.75 to -2.18; p<0.00001) or therapeutical VKAs (MD -1.69; p=0.001) reduced admission stroke severity compared to no anticoagulation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: